Lucid Diagnostics raises $15 million in Series C preferred stock sale
The company sold 15,000 shares of newly created Series C Convertible Preferred Stock to accredited investors, closing October 21, 2026.
SEC filing
Latest
2 stories
Thursday, October 22
Friday, October 16
Lucid Diagnostics gets Nasdaq notice over low stock price
Nasdaq told Lucid Diagnostics on October 12, 2026 that its stock has traded below $1 for 30 straight business days, triggering a compliance deadline.
SEC filing